This project addresses two critical needs in the canine epilepsy field, identification of effective treatments and development of validated outcome measures. Specifically, the proposed prospective, placebo-controlled, pilot clinical trial will identify associations between diet and seizures in canines and test FitBark actigraphy as a potential outcome measure to correlate seizure activity with diet.
The RCAM goals are:
1. To identify hereditary metabolic diseases within the dog and cat population,
2. To develop precise diagnostic tests for carriers and affected animals,
3. To recommend informed breeding of carrier and normal animals to preserve gene pools,
4. To maintain colonies of hereditary disorders in dogs and cats to better understand disease pathogenesis and to develop therapies, and
5. To provide tissues samples and large animal models of human genetic disease to investigators in order to better understand disease pathogenesis and as preclinical models for potential human clinical trials.
Interferon lambda (IFN-λ) is a cytokine that exerts antiviral effects at anatomic barriers but its effects in the skin have not been extensively investigated. We will use transgenic mouse models to study the effects of IFN-λ in viral skin infections as well as in the inflammatory condition atopic dermatitis (eczema).
This team is focused on the interaction between cutaneous immune system and microbes. The main research of this group involves the interaction between Staphylococci and keratinocytes in canine and human skin disorders.
What innovative approaches to tackle medical biofilms are needed? How can we make other stakeholders (e.g. medical care providers, engineers, veterinarians, regulatory bodies and other professionals) aware that biofilms are important?
The Canine Aging and Cognitive Dysfunction research program at Colorado State University, consisting of a multidisciplinary team, uses the dog as an animal disease model to
study aging and cognitive dysfunction. The primary goals of the research program are to develop diagnostic approaches for early identification of cognitive dysfunction, to understand the
mechanism and associated risk factors involved in brain aging and cognitive decline, and to engage in therapeutic translational clinical trials utilizing the dog as a large animal surrogate for
Traditional chemotherapy such as doxorubicin causes cardiac injury, limiting its use in cancer treatment. Dysregulation of the autophagic flux in cardiomyocytes secondary to doxorubicin treatment is known to occur. We aim to understand how this dysregulation contributes to cardiomyocyte cell death, and if the autophagic flux can be manipulated to prevent loss of cardiomyocytes with cancer therapy.
Our group employs a mouse model of pathogenic SARS-CoV-2 infection to study viral pathogenesis and the host response to infection. Information gained from this project will provide insight to how anti-inflammatory therapies play both a protective and pathological role in SARS-CoV-2 infection
Specific areas of research include the development of gene therapies, the genetics of muscular dystrophies, the intersecting roles of environmental exposures and genetics in neurodegenerative diseases (Degenerative Myelopathy, Alzheimer’s, and Parkinson’s disease), and Inherited/Familial cardiomyopathy of dogs and humans (Dilated Cardiomyopathy and Arrhythmogenic Right Ventricular Cardiomyopathy).
The focus of my laboratory is to improve the characterization and treatment of hereditary neurodegenerative diseases by studying naturally-occurring large animal models of human diseases. My laboratory develops and evaluates experimental therapies including gene therapy, cell-based therapy, and pharmacotherapy in canine and feline models, and develops and validates ante-mortem biochemical and magnetic resonance markers of disease severity and progression.
Current projects include genetic investigations of spinal and other musculoskeletal conditions, neurologic diseases such as polyneuropathy, ophthalmic diseases such as pigmentary uveitis in Golden Retrievers, and others (e.g dwarfism, vaccine response).
This fellowship will focus on exploring the immune regulatory (IR) properties of canine regulatory T cells (Tregs) and iNKT cells in vitro and on evaluating the effects of ex vivo activated and expanded IR cells to enable successful allogeneic canine renal transplant or allogeneic off-the-shelf adoptive T cell therapies for dogs with hematological cancers.
The research focuses on understanding how lipid metabolism contributes to osteoarthritis pathophysiology. Specifically, our studies seek to determine both the therapeutic efficacy of cyclooxygenase and soluble epoxide hydrolase inhibition in osteoarthritis and understand the enzymes’ role in osteoarthritis development/progression.
Gut bacteria (microbiota) may contribute to the variable individual responses to IBD drugs. Accurately predicting detrimental or beneficial drug responses for individuals will guide precise, personalized strategies for optimal therapeutic approaches, thus improving quality of life for all IBD patients.
Our research program focuses on the role of nutrition in the development, progression, and treatment of cardiac diseases, including degenerative mitral valve disease, hypertrophic cardiomyopathy, and dilated cardiomyopathy.
The broad objectives of this research are to investigate recombinant lubricin and mucin therapeutics for the treatment of musculoskeletal diseases, including osteoarthritis, orthopedic infection and wound healing.
Register for the site or log in to access and share research, member resources, and more.